| pubmed-article:21671895 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0009247 | lld:lifeskim |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0948008 | lld:lifeskim |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0272285 | lld:lifeskim |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:21671895 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:21671895 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21671895 | pubmed:dateCreated | 2011-7-13 | lld:pubmed |
| pubmed-article:21671895 | pubmed:abstractText | Acute ischaemic stroke patients sometimes receive heparin for treatment and/or prophylaxis of thromboembolic complications. This study was designed to elucidate the incidence and clinical features of heparin-induced thrombocytopenia (HIT) in acute stroke patients treated with heparin. We conducted a prospective multicentre cohort study of 267 patients who were admitted to three stroke centres within 7 d after stroke onset. We examined clinical data until discharge and collected blood samples on days 1 and 14 of hospitalization to test anti-platelet factor 4/heparin antibodies (anti-PF4/H Abs) using an enzyme-linked immunosorbent assay (ELISA); platelet-activating antibodies were identified by serotonin-release assay (SRA). Patients with a 4Ts score ?4 points, positive-ELISA, and positive-SRA were diagnosed as definite HIT. Heparin was administered to 172 patients (64·4%: heparin group). Anti-PF4/H Abs were detected by ELISA in 22 cases (12·8%) in the heparin group. Seven patients had 4Ts ? 4 points. Among them, three patients (1·7% overall) were also positive by both ELISA and SRA. National Institutes of Health Stroke Scale score on admission was high (range, 16-23) and in-hospital mortality was very high (66·7%) in definite HIT patients. In this study, the incidence of definite HIT in acute ischaemic stroke patients treated with heparin was 1·7% (95% confidence interval: 0·4-5·0). The clinical severity and outcome of definite HIT were unfavourable. | lld:pubmed |
| pubmed-article:21671895 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21671895 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21671895 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21671895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21671895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21671895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21671895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21671895 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21671895 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21671895 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:ToyodaKazunor... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:HiranoTeruyuk... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:UchinoMakotoM | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:KawanoHiroyuk... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:MiyataShigeki... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:NaritomiHiroa... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:MinematsuKazu... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:TorataniNaomi... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:WarkentinTheo... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:NagatsukaKazu... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:KadaAkikoA | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:SatoShoichiro... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:OkamotoSadahi... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:YamamotoHaruk... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:SheppardJo-An... | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:IzumiManabuM | lld:pubmed |
| pubmed-article:21671895 | pubmed:author | pubmed-author:KakutaniIsami... | lld:pubmed |
| pubmed-article:21671895 | pubmed:copyrightInfo | © 2011 Blackwell Publishing Ltd. | lld:pubmed |
| pubmed-article:21671895 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21671895 | pubmed:volume | 154 | lld:pubmed |
| pubmed-article:21671895 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21671895 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21671895 | pubmed:pagination | 378-86 | lld:pubmed |
| pubmed-article:21671895 | pubmed:dateRevised | 2011-9-15 | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:meshHeading | pubmed-meshheading:21671895... | lld:pubmed |
| pubmed-article:21671895 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21671895 | pubmed:articleTitle | Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients. | lld:pubmed |
| pubmed-article:21671895 | pubmed:affiliation | Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Osaka, Japan. | lld:pubmed |
| pubmed-article:21671895 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21671895 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:21671895 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21671895 | pubmed:publicationType | Multicenter Study | lld:pubmed |
